MENS says MCS-2 advances with FDA phase III approval
The company says MCS-2 advanced with FDA phase III approval for benign prostatic hyperplasia, and it describes the drug as a botanical option with a strong safety profile.
MCS-2 is recognized for its unique action and strong safety profile in treating benign prostatic hyperplasia. S. FDA phase III approval for a botanical drug, marking regulatory progress. Based on Jyong Biotech Ltd.
[MENS] AGM 2026 Audio Transcript.